Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Alzamend Neuro Inc (ALZN)
Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alzamend Neuro Inc 3480 Peachtree Rd NE Second Floor Suite 103 Atlanta GA 30326 USA

www.alzamend.com P: 844-722-6303

Description:

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Key Statistics

Overview:

Market Capitalization, $K 6,159
Enterprise Value, $K 1,019
Shares Outstanding, K 7,121
Annual Sales, $ 0 K
Annual Net Income, $ -14,880 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,910 K
EBIT, $ -15,160 K
EBITDA, $ -15,140 K
60-Month Beta -0.13
% of Insider Shareholders 10.86%
% of Institutional Shareholders 6.37%
Float, K 6,347
% Float 89.14%
Short Volume Ratio 0.27

Growth:

1-Year Return -89.11%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.44 on 12/15/23
Latest Earnings Date 03/21/24
Earnings Per Share ttm -1.51
EPS Growth vs. Prev Qtr 173.37%
EPS Growth vs. Prev Year 197.83%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 10/31/23

ALZN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -612.26%
Return-on-Assets % -207.52%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.41
Interest Coverage -1,487.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar